Enveric inks $62M licensing deal for psilocin prodrug
Enveric Biosciences (NASDAQ: ENVB) agreed to license one of its experimental psychedelic drug candidates to MycoMedica Life Sciences in a deal worth as much as $62 million, as the biotech company keeps its eye on its non-hallucinogenic treatments. The agreement grants MycoMedica exclusive global rights to EB-002, a synthetic prodrug of psilocin, for treating neuropsychiatric […]
